Equillium Inc (EQ)
$0.93
Performance
- $0.89$1.03$0.93
4.3%
Downside
Day's Volatility :13.25%
Upside
9.35%
- $0.45$3.25$0.93
51.61%
Downside
52 Weeks Volatility :86.15%
Upside
71.38%
Returns
| Period | Equillium Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 15.61% | 0.0% |
6 Months | -65.83% | 0.0% |
1 Year | 13.62% | 0.0% |
3 Years | -83.61% | -22.3% |
Highlights
Market Capitalization | 36.2M |
Book Value | $0.63 |
Earnings Per Share (EPS) | -0.21 |
Wall Street Target Price | 6.75 |
Profit Margin | -19.51% |
Operating Margin TTM | -0.72% |
Return On Assets TTM | -11.95% |
Return On Equity TTM | -33.67% |
Revenue TTM | 42.6M |
Revenue Per Share TTM | 1.21 |
Quarterly Revenue Growth YOY | 51.800000000000004% |
Gross Profit TTM | 15.8M |
EBITDA | -9.6M |
Diluted Eps TTM | -0.21 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.5 |
EPS Estimate Next Year | -1.06 |
EPS Estimate Current Quarter | -0.15 |
EPS Estimate Next Quarter | 0.24 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 625.81%
Technicals Summary
Sell
Neutral
Buy
Equillium Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Equillium Inc | 26.16% | -65.83% | 13.62% | -83.61% | -74.97% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Equillium Inc | NA | NA | NA | -0.5 | -0.34 | -0.12 | NA | 0.63 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Equillium Inc | Buy | $36.2M | -74.97% | NA | -19.51% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Equillium Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 23.5%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 152.8%
Institutional Holdings
Decheng Capital LLC
12.55%Vanguard Group Inc
2.38%Renaissance Technologies Corp
0.59%Geode Capital Management, LLC
0.56%ADAR1 Capital Management LLC
0.40%Acadian Asset Management LLC
0.31%
Company Information
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
Organization | Equillium Inc |
Employees | 45 |
CEO | Mr. Daniel Mark Bradbury |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$0.93
-5.51%
Keyarch Acquisition Corp
$0.93
-5.51%
Connexa Sports Technologies Inc
$0.93
-5.51%
Us Value Etf
$0.93
-5.51%
First Wave Biopharma Inc
$0.93
-5.51%
Global X Msci Next Emerging
$0.93
-5.51%
Fat Projects Acquisition Corp
$0.93
-5.51%
Capital Link Global Fintech
$0.93
-5.51%
Applied Uv Inc
$0.93
-5.51%